Safety Profile
Ipamorelin
Updated today
GH Secretagogue PeptideHow we score compound safety →
Regulatory Status
Safety Summary
- Most selective GHRP
- minimal cortisol/prolactin
- human PK data
- widely used with good anecdotal safety
Ipamorelin's 7/10 rating reflects mixed evidence — some clinical data and a meaningful research base, but enough open questions that researchers should weight personal risk tolerance heavily. Long-term safety in the population segment most likely to use this compound (off-label) is the area with the thinnest published evidence. Researchers often consider CJC-1295 and Tesamorelin as alternatives in the same category — see the related-compounds section below for safety comparisons.
Molecular Profile
Storage
- Protect from light
- Avoid repeated freeze-thaw
- Use bacteriostatic water
Related Compounds
Methodology
How we rate peptide safety
Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.
- 40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
- 30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
- 20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
- 10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.
Related compounds
Other compounds researchers compare with Ipamorelin
Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.
